What the research found
Pevnick and colleagues' PHARM-DC trial, published in March 2026, analyzed 6,428 hospitalizations at two academic centers. In the group with Medicare claims available, additional pharmacist-led discharge care did not significantly reduce thirty-day unplanned hospital or emergency use. Both groups received substantial admission medication-reconciliation support, and delivery of intervention components was incomplete. The result concerns the incremental service tested against that comparator. [1]
The earlier MI FREEE trial by Choudhry and colleagues tested elimination of copayments for selected preventive medicines after myocardial infarction. It improved adherence and reduced patient spending, but did not significantly improve the primary composite outcome. This is foundational 2011 evidence about a financial-access mechanism, not a current price estimate or a universal savings guarantee. [2]
My operator interpretation
I would begin by identifying the unresolved medication decision. A person may need an appropriate prescription, an affordable benefit route, a pharmacy able to dispense it, understandable instructions or clinical reassessment. These are different barriers, and a service should not claim to solve them simply because it produces a medication list or sends reminders.
The business case should specify what is added to existing care. If the organization already provides strong reconciliation, the next pharmacist hour might be better directed toward an unresolved access problem or a patient who needs more intensive support. That is an allocation hypothesis to evaluate with clinical leadership, not an inference that the trial proved any particular targeting policy.
I would follow the pathway from prescribed to obtainable, dispensed, understood and clinically reviewed. Claims can indicate a transaction or refill pattern, while the patient and care team clarify what is actually happening. A measured gap should prompt an appropriate conversation rather than automatically trigger pressure to continue a medicine.
The economic model needs separate views of patient expense, drug spending, service cost and any change in acute utilization. Reducing an individual's out-of-pocket burden can be a worthwhile outcome even when the institution cannot establish a short-term medical offset. A purchaser should know which benefit it is paying for and which outcome remains uncertain.
The decision I would make
I would fund a bounded pharmacy service around a documented barrier, with completion measures, patient feedback and the full cost of professional follow-through. Any utilization promise would require its own comparative evaluation. The two trials inform the mechanism and comparator; they do not supply a ready-made return assumption for a new pharmacy business.
What this evidence cannot settle
The trials test different populations and mechanisms and should not be pooled into one effect. Neither establishes the return of the proposed local service.